PreciseDx

Company profile

About PreciseDx

PreciseDx is a pathology and laboratory diagnostics company that has developed OncoIntelligence™, a proprietary AI platform for cancer diagnosis and risk assessment. The company's flagship product, PreciseBreast®, revolutionizes breast cancer care by combining AI-grade analysis with key clinical factors to produce an OncoIntelligence Score™ that accurately stratifies patients based on disease recurrence risk up to 8.8 years. The technology has been clinically validated in more than 1,600 breast cancer cases and analyzes cellular morphology from existing tissue samples—the same slides pathologists use for tumor grading—examining every cell to ensure accurate, quantitative data. Unlike traditional gene expression testing that can take 2-6 weeks and cost over $4,000, PreciseBreast® delivers objective results in hours at approximately 30% of the cost. Founded by Dr. Carlos Cordon-Cardo, a pioneer in molecular pathology and systems pathology, PreciseDx serves oncologists, surgeons, pathologists, payers, and patients. The company addresses a critical gap in breast cancer diagnosis where 50% of tumors are categorized as intermediate Grade 2, with high intra-observer variation (65%) in traditional grading. PreciseBreast® provides comprehensive insight into tumor phenotype and grade, refining pathologic assessment and medical decisions while offering global equity for women facing breast cancer diagnosis.

Company description · PreciseDx official website